Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (61-70 of 118) with videos related to

Pageof 12
Sort By:
Clinical Trials (London, England)|October 3, 2013
Marker Sequential Test (MaST) designBoris Freidlin, Edward L Korn, Robert Gray
JCO Oncology Advances|January 6, 2025
Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology TrialsChen Hu, Boris Freidlin, Edward L Korn
Controlled Clinical Trials|February 26, 2004
Data monitoring and large apparent treatment effectsEdward L Korn, Boris Freidlin, Stephen L George
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancerBoris Freidlin, Oscar S Breathnach, Bruce E Johnson
Journal of the National Cancer Institute|May 18, 2022
Clinical Benefit Scales and Trial Design: Some Statistical IssuesEdward L Korn, Carmen J Allegra, Boris Freidlin
The New England Journal of Medicine|April 21, 2021
Platform Trials - Beware the Noncomparable Control GroupLori E Dodd, Boris Freidlin, Edward L Korn
Journal of the National Cancer Institute|December 24, 2019
Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?Boris Freidlin, Carmen J Allegra, Edward L Korn
Clinical Trials (London, England)|September 8, 2010
Measurement error in the timing of events: effect on survival analyses in randomized clinical trialsEdward L Korn, Lori E Dodd, Boris Freidlin
Journal of Comparative Effectiveness Research|November 19, 2013
New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trialsBoris Freidlin, Jeffrey S Abrams, Edward L Korn
Statistics in Medicine|August 19, 2004
Strength of accumulating evidence and data monitoring committee decision makingStephen L George, Boris Freidlin, Edward L Korn
Pageof 12

Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Clinical Trials (London, England)|October 3, 2013
Marker Sequential Test (MaST) designBoris Freidlin, Edward L Korn, Robert Gray
JCO Oncology Advances|January 6, 2025
Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology TrialsChen Hu, Boris Freidlin, Edward L Korn
Controlled Clinical Trials|February 26, 2004
Data monitoring and large apparent treatment effectsEdward L Korn, Boris Freidlin, Stephen L George
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancerBoris Freidlin, Oscar S Breathnach, Bruce E Johnson
Journal of the National Cancer Institute|May 18, 2022
Clinical Benefit Scales and Trial Design: Some Statistical IssuesEdward L Korn, Carmen J Allegra, Boris Freidlin
The New England Journal of Medicine|April 21, 2021
Platform Trials - Beware the Noncomparable Control GroupLori E Dodd, Boris Freidlin, Edward L Korn
Journal of the National Cancer Institute|December 24, 2019
Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?Boris Freidlin, Carmen J Allegra, Edward L Korn
Clinical Trials (London, England)|September 8, 2010
Measurement error in the timing of events: effect on survival analyses in randomized clinical trialsEdward L Korn, Lori E Dodd, Boris Freidlin
Journal of Comparative Effectiveness Research|November 19, 2013
New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trialsBoris Freidlin, Jeffrey S Abrams, Edward L Korn
Statistics in Medicine|August 19, 2004
Strength of accumulating evidence and data monitoring committee decision makingStephen L George, Boris Freidlin, Edward L Korn
Pageof 12